Member, Center for Infection & Immunity
Principal Investigator, Department of Interdisciplinary Arts and Sciences, University of Washington Tacoma
EDUCATION & TRAINING
Washington State University, Pullman, WA, BS, 1984
The Weizmann Institute of Science, Rehovot, Israel, MS, 1991
The Weizmann Institute of Science, Rehovot, Israel, PhD, 1996
Stanford University School of Medicine, Stanford, CA, Postdoctoral Fellow, 2000
Research Associate II, Oncogen, Subsidiary of Bristol Myers-Squibb, Seattle, WA , 1985-88
Research Scientist, Agilent Technologies, Life Sciences and Chemical Analysis Division, Palo Alto/Santa Clara, CA, 2000-2006
Assistant Professor of Clinical Pathology, Center for Infection & Immunity, Columbia Univeristy, New York, NY, 2006-2014
BIO AND SCIENTIFIC INTERESTS
David Hirschberg, PhD is Assistant Professor of Clinical Pathology in the Mailman School of Public Health and the Chief Technology Officer for the Center for Infection and Immunity at Columbia University. A Neuroimmunologist, by training, Dr. Hirschberg is focused on developing technologies that can rapidly identify emerging pathogens either directly or by host response biomarker profiling. Dr. Hirschberg has been an active collaborator Ian Lipkin’s group since 2004. During this time he contributed to developing rapid diagnostics that are currently used to identify multiple microbes in host samples. These technologies include MassTag, pathogen microarrays and unbiased high-throughput sequencing. Since joining the CII in 2009, he has set up a internal core facility with capability to rapidly id pathogen sequence novel pathogens using in situ branched DNA technology and adapted a number proteomic biomarkers assays to further complement the repertoire of characterization assays at the CII.
Prior to joining the Center for Infection and Immunity, Dr. Hirschberg was involved in the inception and development of the Human Immune Monitoring Center at Stanford University Medical School. This state-of-the-art facility was established to bring outside researchers and companies together with Stanford researchers to accelerate technology transfer to the clinic and field.
Dr. Hirschberg was a Senior Research Scientist at Agilent Technologies where he created new applications for Agilent’s genomic and proteomic platforms. He interacted with thought-leaders in academia and industry, developing new strategies and proof-of-concept experiments that led to peer-reviewed publications and fieldable products. Dr. Hirschberg developed better ways to measure biomarkers on genomic, proteomic and metabolomic levels, and adapted Agilent’s product line to clinical research and diagnostics. He was involved in the design and validation of Agilent’s DNA microarrays, as well as several protein arrays prototypes. Dr. Hirschberg also made antibody therapeutics to tumor-associated antigens while working for Bristol Meyers Squibb.
Dr. Hirschberg received his doctoral degree from the Weizmann Institute of Science in Neuroimmunology. He completed postdoctoral training in the Department of Neurology at Stanford Medical School studying autoimmune disease. He is the author of a number of patents and has consulted for various biotechnology companies. He co-founded NeuroPro, a company developing products to promote nerve regeneration following injury and BayHill Therapeutics, a company developing DNA vaccinations to tolerize against autoimmune disease. He currently serves on the scientific advisory boards of Revalesio Inc, Gemio Technologies, Inc, and Diacarta.
- Palacios G, Lovoll M, Tengs T, Hornig M, Hutchison S, Hui J, Kongtorp RT, Savji N, Bussetti AV, Solovyov A, Kristoffersen AB, Celone C, Street C, Trifonov V, Hirschberg DL, Rabadan R, Egholm M, Rimstad E, Lipkin WI. Heart and skeletal muscle inflammation of farmed salmon is associated with infection with a novel reovirus. PLoS One. 2010 Jul 9;5(7):e11487
- Cameron B, Hirschberg DL, Rosenberg-Hassan Y, Ablashi D, Lloyd AR. Serum cytokine levels in postinfective fatigue syndrome. Clin Infect Dis. 2010;50(2):278-9.
- Walley JW, Kelley DR, Nestorova G, Hirschberg DL, Dehesh K. Arabidopsis Deadenylases AtCAF1a and AtCAF1b Play Overlapping and Distinct Roles in Mediating Environmental Stress Responses. Plant Physiol. 2010;152(2):866-75. PMCID: 2815882.
- Yang Q, El-Sayed Y, Rosenberg-Hasson Y, Hirschberg DL, Nayak NR, Schilling J, Madan A. Multiple cytokine profile in plasma and amniotic fluid in a mouse model of pre-term labor. Am J Reprod Immunol. 2009;62(5):339-47.
- Shen-Orr SS, Goldberger O, Garten Y, Rosenberg-Hasson Y, Lovelace PA, Hirschberg DL, Altman RB, Davis MM, Butte AJ (2009) Towards a cytokine-cell integration knowledgebase of he adaptive immune system. Pacific Symposium on Biocomputing 2009, 14: 439-450
- Wilson KD, Li Z, Wagner R, Yue P, Tsao P, Nestorova G, Huang M, Hirschberg DL, Yock PG, Quertermous T, Wu JC (2008) Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality. PLoS ONE, 3(7): e2609
- Palacios G, Quan P-L, Jabado OJ, Conlan S, Hirschberg DL, Liu Y, et al. (2007) Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis, 13(1): 73-81 (http://www.cdc.gov/ncidod/EID/13/1//73.htm)
- Quan PL, Palacios G, Jabado OJ, Conlan S, Hirschberg DL, Pozo F, Jack PJ, Cisterna D, Renwick N, Hui J, Drysdale A, Amos-Ritchie R, Baumeister E, Savy V, Lager KM, Richt JA, Boyle DB, García-Sastre A, Casas I, Perez-Breña P, Briese T, Lipkin WI (2007) Detection of respiratory viruses and subtype identification of influenza A viruses by GreeneChipResp oligonucleotide microarray. J Clin Microbiol, 45(8): 2359-2364.
- Robinson W, DiGennaro HC, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL, Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO, Steinman L, Utz PJ (2002) Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med, 8(3): 295-301
- Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS (2002) The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol, 169(12): 6720-6732